Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ImmunityBio, Inc. IBRX
$2.30
-$0.41 (-17.74%)
На 18:04, 12 мая 2023
+247.83%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2688454366.00000000
-
week52high
7.80
-
week52low
1.21
-
Revenue
240000
-
P/E TTM
-5
-
Beta
-0.43790400
-
EPS
-1.22000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 04:00
Описание компании
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Buy | 03 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Adcock Richard | D | 155180 | 8620 | 31 дек 2022 г. |
| Adcock Richard | D | 144441 | 4273 | 31 дек 2022 г. |
| Adcock Richard | A | 148714 | 8620 | 31 дек 2022 г. |
| Sachs David C. | D | 136793 | 7598 | 31 дек 2022 г. |
| Sachs David C. | A | 51298 | 7598 | 31 дек 2022 г. |
| SOON-SHIONG PATRICK | A | 9986920 | 9986920 | 12 дек 2022 г. |
| MAXWELL LINDA | A | 167937 | 167937 | 14 июн 2022 г. |
| Selecky Christobel | A | 167937 | 167937 | 14 июн 2022 г. |
| Clark Wesley | A | 167937 | 167937 | 14 июн 2022 г. |
| Cohen Cheryl | A | 167937 | 167937 | 14 июн 2022 г. |
Новостная лента
ImmunityBio: Upcoming PDUFA, Solid Data, Confusing Finances
Seeking Alpha
06 янв 2023 г. в 14:15
ImmunityBio, Inc. presented strong data from its lead asset in multiple indications. Lead indication has a May 23 PDUFA.
ImmunityBio: PDUFA Pending
Seeking Alpha
17 окт 2022 г. в 08:37
ImmunityBio operates an effective development program for infectious disease, and more interestingly, oncology therapies. Its duly accepted BLA will be in the spotlight as its PDUFA date rolls around.
7 Unknown Biotech Stocks That Could Rocket in 2023
InvestorPlace
23 сент 2022 г. в 07:30
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain
Seeking Alpha
07 авг 2022 г. в 09:59
Shares of ImmunityBio have lost nearly 90% of their value since merger with NantKwest last year. Ties to biotech billionaire Patrick Soon-Shiong are a net positive, especially in light of his success selling prior company Abraxis to Pfizer for $2.9 billion.
7 Best Pharmaceutical Stocks to Buy Now
InvestorPlace
20 июл 2022 г. в 18:00
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.